The case for Zostavax vaccination in systemic lupus erythematosus
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AR053483, AI082714, GM103456)
This publication has 30 references indexed in Scilit:
- Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort studyInfection, 2011
- A Prospective Study of the Herpes Zoster Severity of IllnessThe Clinical Journal of Pain, 2010
- Zoster Vaccine: Current Status and Future ProspectsClinical Infectious Diseases, 2010
- Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus ErythematosusJCR: Journal of Clinical Rheumatology, 2010
- Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and OutcomesAutoimmune Diseases, 2010
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Herpes zoster in Japanese patients with systemic lupus erythematosusClinical and Experimental Dermatology, 1999
- Susceptibility of Oka varicella vaccine strain to antiviral drugsVaccine, 1993
- High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis.Annals of the Rheumatic Diseases, 1990
- Herpes zoster in patients with systemic lupus erythematosusArthritis & Rheumatism, 1978